[Natural immunity--first line defense. New treatment against infections and autoimmune diseases in sight].
Bergman
Peter
P
Klinisk mikrobiologi, Karolinska Universitetssjukhuset Huddinge. peter.bergman@karolinska.se
Gudmundsson
Gudmundur H
GH
Agerberth
Birgitta
B
D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D054804:Cathelicidins / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D007150:Immunohistochemistry; D054806:Magainins / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use; D011971:Receptors, Immunologic / Q000276:immunology; D023084:alpha-Defensins / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use; D023083:beta-Defensins / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use
D023181:Antimicrobial Cationic Peptides; D054804:Cathelicidins; D054806:Magainins; D011971:Receptors, Immunologic; D023084:alpha-Defensins; D023083:beta-Defensins